Celtic Pharma And Russia's Rusnano Set Up Pro Bono Bio, A New Firm With Philanthropic Objectives
This article was originally published in PharmAsia News
Executive Summary
A new pharmaceutical company, Pro Bono Bio, has been set up by private equity firm Celtic Pharma Holdings in London and a Russian government investment vehicle, Rusnano, and has launched its first product, an analgesic gel, Flexiseq, which works by sequestering arachidonic acid and is approved as a medical device in Europe